{"id":1091,"date":"2021-06-09T00:48:57","date_gmt":"2021-06-08T21:48:57","guid":{"rendered":"https:\/\/www.lbscience.org\/en\/2025\/09\/09\/the-cure-for-alzheimers\/"},"modified":"2025-10-01T04:46:29","modified_gmt":"2025-10-01T01:46:29","slug":"the-cure-for-alzheimers","status":"publish","type":"post","link":"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/","title":{"rendered":"The Cure for Alzheimer\u2019s?"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Alzheimer\u2019s disease primarily affects older adults who experience cognitive decline, characterized by disorientation and memory loss. In patients with the disease there is an accumulation of a protein called amyloid-\u03b2 and of a protein called tau. Both processes cause neuronal death and, consequently, cognitive decline [<\/span><span style=\"font-weight: 400;\">1<\/span><span style=\"font-weight: 400;\">].<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Over the past three decades more than 2,000 clinical trials have been conducted worldwide in an attempt to find a cure for Alzheimer\u2019s disease, with roughly a quarter of these trials directed at amyloid-\u03b2, based on the idea that reducing the accumulation of this protein would delay the onset of Alzheimer\u2019s symptoms [<\/span><span style=\"font-weight: 400;\">2<\/span><span style=\"font-weight: 400;\">]. Despite these hundreds of trials, no single treatment targeting amyloid-\u03b2 has yet proven effective in delaying the appearance of disease symptoms, even though some have succeeded in preventing amyloid-\u03b2 accumulation.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Consequently, researchers began searching for other factors suspected of involvement in the pathological process of Alzheimer\u2019s, and the number of proponents of amyloid-\u03b2\u2013targeted therapies declined. Yet several strong arguments keep this camp alive. First, in 1\u20135 percent of Alzheimer\u2019s patients a single genetic factor causes the disease, and this factor is involved in increased production of amyloid-\u03b2 in the brain [<\/span><span style=\"font-weight: 400;\">3<\/span><span style=\"font-weight: 400;\">]. Another reason is that chromosome 21, present in three copies in people with Down syndrome, carries the Amyloid Precursor Protein (APP) gene that encodes the APP protein from which amyloid-\u03b2 is generated; this protein has been shown to be responsible for cognitive decline in those individuals [<\/span><span style=\"font-weight: 400;\">4<\/span><span style=\"font-weight: 400;\">]. Amyloid-\u03b2 accumulation is toxic to neurons, and the protein has also been shown to trigger tau pathology [<\/span><span style=\"font-weight: 400;\">5, 6<\/span><span style=\"font-weight: 400;\">]. Tau accumulation occurs in the brains of Alzheimer\u2019s patients shortly before the first clinical symptoms. Chronologically, amyloid-\u03b2 deposition precedes tau accumulation, and immediately afterward early memory-loss symptoms emerge.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In 2007 the American company Biogen purchased an antibody against amyloid-\u03b2, developed by a firm called Neuroimmune, for about $380 million [<\/span><span style=\"font-weight: 400;\">7<\/span><span style=\"font-weight: 400;\">]. This antibody can bind single amyloid-\u03b2 units, oligomers (protein chains), and large aggregates in the brain known as amyloid plaques. Binding of the antibody to oligomers and plaques recruits microglia, which act to dismantle these protein accumulations.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In March 2015, the results of phase 1a of the first clinical trial of the drug were reported. In August 2016, the phase 1b results were published. In a puzzling move, the U.S. Food and Drug Administration (FDA) did not require Biogen to conduct a phase 2 trial. In September 2016 the company initiated phase 3 trials, named ENGAGE and EMERGE. In March 2019, at the height of trials involving 3,482 participants, Biogen halted development after an interim analysis showed that treatment outcomes did not meet the predefined endpoints [<\/span><span style=\"font-weight: 400;\">8<\/span><span style=\"font-weight: 400;\">].<\/span><\/p>\n<p><span style=\"font-weight: 400;\">From this point the major controversy surrounding the drug\u2019s approval began. In October 2019, Biogen announced that a new statistical analysis conducted by an independent research group showed a 23 percent reduction in cognitive decline in one treatment group in the EMERGE trial that had received the highest dose tested so far [<\/span><span style=\"font-weight: 400;\">9<\/span><span style=\"font-weight: 400;\">]. In the parallel ENGAGE trial, the reduction was only 2 percent. The company\u2019s explanation that the differences arose from technical factors\u2014such as different trial start dates and patients switching to higher doses during the study\u2014was met with skepticism by many critics [<\/span><span style=\"font-weight: 400;\">9<\/span><span style=\"font-weight: 400;\">].<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Although in November 2020 an external FDA advisory panel recommended against approving the drug, citing low efficacy and problems with data analysis, on June 7, 2021 the FDA approved the drug through an \u201caccelerated approval\u201d pathway [<\/span><span style=\"font-weight: 400;\">10<\/span><span style=\"font-weight: 400;\">]. This pathway is granted to drugs intended for life-threatening diseases or diseases with no existing effective therapy and may rely on data indicating a reasonable likelihood of clinical benefit\u2014in this case, slowing cognitive decline in Alzheimer\u2019s patients.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">However, \u201caccelerated approval\u201d comes with fine print: the company that developed the drug is required to conduct a large-scale clinical trial that must conclusively demonstrate significant clinical efficacy. If this trial shows no meaningful effect on disease progression, the FDA may withdraw the accelerated approval and thereby ban distribution of the drug.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Immediately after the FDA announcement, several U.S. physicians and researchers stated that, in their view, the drug\u2019s benefits do not justify its risks. Reasons included: (a) a marginal effect on the rate of cognitive decline; (b) a potential side effect called ARIA\u2014Amyloid Related Imaging Abnormality\u2014essentially local inflammation detectable by imaging. This occurs in about half of treated patients, apparently due to immune activation after the antibody enters the brain and binds its target, amyloid-\u03b2. Clinical manifestations include headaches, mood changes, confusion, vomiting, nausea, tremor, and movement problems. Nevertheless, ARIA is not considered severe and can be managed with corticosteroids such as dexamethasone. (c) The price of the drug for insured patients is still unknown, but Biogen has announced an annual cost of $56,000.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Today we know that Alzheimer\u2019s disease develops \u201cunder the hood\u201d for roughly two decades before symptoms appear, manifesting as a measurable condition called mild cognitive impairment, characterized through neurocognitive testing by neurologists. Researchers who support the drug\u2019s efficacy argue that the earlier it is administered\u2014before the first symptoms emerge\u2014the more effective it will be. Implementing this is particularly difficult because there are currently no indicators for early diagnosis of the disease.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Time will tell whether Biogen\u2019s Alzheimer\u2019s drug will be effective in real-world use and what impact it will have on the pharmaceutical market and on research into the disease. For now, the approval announcement was received with low enthusiasm from professionals, while patients and their families await the medication with great anticipation.<\/span><\/p>\n<p>English editing: Elee Shimshoni<\/p>\n<hr \/>\n<p><strong>References:<\/strong><\/p>\n<p><span style=\"font-weight: 400;\">[1] <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/24493463\/\">Article discussing the link between amyloid and tau in Alzheimer\u2019s disease:<\/a><\/span><\/p>\n<p><span style=\"font-weight: 400;\">[2] <a href=\"https:\/\/www.nature.com\/articles\/s41392-019-0063-8\">Article summarizing all Alzheimer\u2019s clinical trials up to 2019:<\/a><\/span><\/p>\n<p><span style=\"font-weight: 400;\">[3] <\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5370101\/\"><span style=\"font-weight: 400;\">Article describing the genetic factors in early-onset Alzheimer\u2019s disease:<\/span><\/a><\/p>\n<p><span style=\"font-weight: 400;\">[4] <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27983553\/\">Article showing that APP is responsible for cognitive decline in people with Down syndrome<\/a><\/span><\/p>\n<p><span style=\"font-weight: 400;\">[5]<a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0002944017300809\">Articles demonstrating that amyloid-\u03b2 induces tau pathology in Alzheimer\u2019s disease:<\/a><\/span><\/p>\n<p><span style=\"font-weight: 400;\">[6]<\/span><a href=\"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/1750-1326-9-51\"> <span style=\"font-weight: 400;\">https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/1750-1326-9-51<\/span><\/a><\/p>\n<p><span style=\"font-weight: 400;\">[7] <\/span><a href=\"https:\/\/xconomy.com\/boston\/2007\/11\/20\/biogen-inks-380-million-deal-with-swiss-company\/\"><span style=\"font-weight: 400;\">Report on Biogen\u2019s acquisition of Neuroimmune:<\/span><\/a><\/p>\n<p><span style=\"font-weight: 400;\">[8] <a href=\"http:\/\/newsroom.biogen.com\/news-releases\/news-release-details\/biogen-and-eisai-discontinue-phase-3-engage-and-emerge-trials\">Biogen press release on halting the aducanumab clinical trial:<\/a><\/span><\/p>\n<p><span style=\"font-weight: 400;\">[9] <a href=\"https:\/\/www.nature.com\/articles\/s41582-019-0295-9\">Discussion of the surprising turnaround in aducanumab efficacy analysis:<\/a><\/span><\/p>\n<p><span style=\"font-weight: 400;\">[10] <a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug?fbclid=IwAR2bDDcaiH6nc5vQL-M0OS9y3Jv8RMhLmyxB8rHrYU6pcoyWJcPEgBqY5cM\">FDA press release regarding aducanumab approval<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alzheimer\u2019s disease primarily affects older adults who experience cognitive decline, characterized by disorientation and memory loss. In patients with the disease there is an accumulation of a protein called amyloid-\u03b2 and of a protein called tau. Both processes cause neuronal death and, consequently, cognitive decline [1]. Over the past three decades more than 2,000 clinical [&hellip;]<\/p>\n","protected":false},"author":134,"featured_media":1167,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-1091","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicine"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The Cure for Alzheimer\u2019s? - Little, Big Science<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Cure for Alzheimer\u2019s? - Little, Big Science\" \/>\n<meta property=\"og:description\" content=\"Alzheimer\u2019s disease primarily affects older adults who experience cognitive decline, characterized by disorientation and memory loss. In patients with the disease there is an accumulation of a protein called amyloid-\u03b2 and of a protein called tau. Both processes cause neuronal death and, consequently, cognitive decline [1]. Over the past three decades more than 2,000 clinical [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/\" \/>\n<meta property=\"og:site_name\" content=\"Little, Big Science\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-08T21:48:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-01T01:46:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/09\/website_meme-9-2048x1152-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"1152\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u05e4\u05e8\u05d5\u05e4\u05f3 \u05d0\u05d9\u05ea\u05df \u05d0\u05d5\u05e7\u05d5\u05df\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@EitanOkun\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u05e4\u05e8\u05d5\u05e4\u05f3 \u05d0\u05d9\u05ea\u05df \u05d0\u05d5\u05e7\u05d5\u05df\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/\",\"url\":\"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/\",\"name\":\"The Cure for Alzheimer\u2019s? - Little, Big Science\",\"isPartOf\":{\"@id\":\"https:\/\/www.lbscience.org\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/09\/website_meme-9-2048x1152-1.jpg\",\"datePublished\":\"2021-06-08T21:48:57+00:00\",\"dateModified\":\"2025-10-01T01:46:29+00:00\",\"author\":{\"@id\":\"https:\/\/www.lbscience.org\/en\/#\/schema\/person\/0c8102b904618058fc9f0fe55676cad1\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/#primaryimage\",\"url\":\"https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/09\/website_meme-9-2048x1152-1.jpg\",\"contentUrl\":\"https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/09\/website_meme-9-2048x1152-1.jpg\",\"width\":2048,\"height\":1152},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.lbscience.org\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Cure for Alzheimer\u2019s?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.lbscience.org\/en\/#website\",\"url\":\"https:\/\/www.lbscience.org\/en\/\",\"name\":\"Little, Big Science\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.lbscience.org\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.lbscience.org\/en\/#\/schema\/person\/0c8102b904618058fc9f0fe55676cad1\",\"name\":\"\u05e4\u05e8\u05d5\u05e4\u05f3 \u05d0\u05d9\u05ea\u05df \u05d0\u05d5\u05e7\u05d5\u05df\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.lbscience.org\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a4b99ecb659aed45756c698137f596da?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a4b99ecb659aed45756c698137f596da?s=96&d=mm&r=g\",\"caption\":\"\u05e4\u05e8\u05d5\u05e4\u05f3 \u05d0\u05d9\u05ea\u05df \u05d0\u05d5\u05e7\u05d5\u05df\"},\"description\":\"\u05e8\u05d0\u05e9 \u05d4\u05de\u05e2\u05d1\u05d3\u05d4 \u05dc\u05d7\u05e7\u05e8 \u05d6\u05d9\u05db\u05e8\u05d5\u05df, \u05dc\u05de\u05d9\u05d3\u05d4 \u05d5\u05de\u05d7\u05dc\u05d5\u05ea \u05e0\u05d9\u05d5\u05d5\u05df \u05e2\u05e6\u05d1\u05d9 \u05d1\u05e4\u05e7\u05d5\u05dc\u05d8\u05d4 \u05dc\u05de\u05d3\u05e2\u05d9 \u05d4\u05d7\u05d9\u05d9\u05dd \u05d5\u05d1\u05de\u05e8\u05db\u05d6 \u05dc\u05d7\u05e7\u05e8 \u05d4\u05de\u05d5\u05d7 \u05d1\u05d0\u05d5\u05e0\u05d9\u05d1\u05e8\u05e1\u05d9\u05d8\u05ea \u05d1\u05e8 \u05d0\u05d9\u05dc\u05df. \u05d7\u05d5\u05e7\u05e8 \u05d0\u05ea \u05de\u05e2\u05d5\u05e8\u05d1\u05d5\u05ea \u05de\u05e2\u05e8\u05db\u05ea \u05d4\u05d7\u05d9\u05e1\u05d5\u05df \u05d1\u05de\u05d7\u05dc\u05d5\u05ea \u05e0\u05d9\u05d5\u05d5\u05df \u05e2\u05e6\u05d1\u05d9 \u05d5\u05d0\u05ea \u05d4\u05de\u05e0\u05d2\u05e0\u05d5\u05e0\u05d9\u05dd \u05d3\u05e8\u05db\u05dd \u05e4\u05e2\u05d9\u05dc\u05d5\u05ea \u05d2\u05d5\u05e4\u05e0\u05d9\u05ea \u05de\u05e9\u05e4\u05d9\u05e2\u05d4 \u05e2\u05dc \u05e4\u05dc\u05e1\u05d8\u05d9\u05d5\u05ea \u05de\u05d5\u05d7\u05d9\u05ea \u05d5\u05ea\u05d4\u05dc\u05d9\u05db\u05d9 \u05dc\u05de\u05d9\u05d3\u05d4 \u05d5\u05d6\u05d9\u05db\u05e8\u05d5\u05df.\",\"sameAs\":[\"https:\/\/x.com\/EitanOkun\"],\"url\":\"https:\/\/www.lbscience.org\/en\/author\/eitan-okun\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Cure for Alzheimer\u2019s? - Little, Big Science","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/","og_locale":"en_US","og_type":"article","og_title":"The Cure for Alzheimer\u2019s? - Little, Big Science","og_description":"Alzheimer\u2019s disease primarily affects older adults who experience cognitive decline, characterized by disorientation and memory loss. In patients with the disease there is an accumulation of a protein called amyloid-\u03b2 and of a protein called tau. Both processes cause neuronal death and, consequently, cognitive decline [1]. Over the past three decades more than 2,000 clinical [&hellip;]","og_url":"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/","og_site_name":"Little, Big Science","article_published_time":"2021-06-08T21:48:57+00:00","article_modified_time":"2025-10-01T01:46:29+00:00","og_image":[{"width":2048,"height":1152,"url":"https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/09\/website_meme-9-2048x1152-1.jpg","type":"image\/jpeg"}],"author":"\u05e4\u05e8\u05d5\u05e4\u05f3 \u05d0\u05d9\u05ea\u05df \u05d0\u05d5\u05e7\u05d5\u05df","twitter_card":"summary_large_image","twitter_creator":"@EitanOkun","twitter_misc":{"Written by":"\u05e4\u05e8\u05d5\u05e4\u05f3 \u05d0\u05d9\u05ea\u05df \u05d0\u05d5\u05e7\u05d5\u05df","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/","url":"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/","name":"The Cure for Alzheimer\u2019s? - Little, Big Science","isPartOf":{"@id":"https:\/\/www.lbscience.org\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/#primaryimage"},"image":{"@id":"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/09\/website_meme-9-2048x1152-1.jpg","datePublished":"2021-06-08T21:48:57+00:00","dateModified":"2025-10-01T01:46:29+00:00","author":{"@id":"https:\/\/www.lbscience.org\/en\/#\/schema\/person\/0c8102b904618058fc9f0fe55676cad1"},"breadcrumb":{"@id":"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/#primaryimage","url":"https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/09\/website_meme-9-2048x1152-1.jpg","contentUrl":"https:\/\/www.lbscience.org\/en\/wp-content\/uploads\/sites\/3\/2025\/09\/website_meme-9-2048x1152-1.jpg","width":2048,"height":1152},{"@type":"BreadcrumbList","@id":"https:\/\/www.lbscience.org\/en\/2021\/06\/09\/the-cure-for-alzheimers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.lbscience.org\/en\/"},{"@type":"ListItem","position":2,"name":"The Cure for Alzheimer\u2019s?"}]},{"@type":"WebSite","@id":"https:\/\/www.lbscience.org\/en\/#website","url":"https:\/\/www.lbscience.org\/en\/","name":"Little, Big Science","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lbscience.org\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.lbscience.org\/en\/#\/schema\/person\/0c8102b904618058fc9f0fe55676cad1","name":"\u05e4\u05e8\u05d5\u05e4\u05f3 \u05d0\u05d9\u05ea\u05df \u05d0\u05d5\u05e7\u05d5\u05df","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.lbscience.org\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/a4b99ecb659aed45756c698137f596da?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a4b99ecb659aed45756c698137f596da?s=96&d=mm&r=g","caption":"\u05e4\u05e8\u05d5\u05e4\u05f3 \u05d0\u05d9\u05ea\u05df \u05d0\u05d5\u05e7\u05d5\u05df"},"description":"\u05e8\u05d0\u05e9 \u05d4\u05de\u05e2\u05d1\u05d3\u05d4 \u05dc\u05d7\u05e7\u05e8 \u05d6\u05d9\u05db\u05e8\u05d5\u05df, \u05dc\u05de\u05d9\u05d3\u05d4 \u05d5\u05de\u05d7\u05dc\u05d5\u05ea \u05e0\u05d9\u05d5\u05d5\u05df \u05e2\u05e6\u05d1\u05d9 \u05d1\u05e4\u05e7\u05d5\u05dc\u05d8\u05d4 \u05dc\u05de\u05d3\u05e2\u05d9 \u05d4\u05d7\u05d9\u05d9\u05dd \u05d5\u05d1\u05de\u05e8\u05db\u05d6 \u05dc\u05d7\u05e7\u05e8 \u05d4\u05de\u05d5\u05d7 \u05d1\u05d0\u05d5\u05e0\u05d9\u05d1\u05e8\u05e1\u05d9\u05d8\u05ea \u05d1\u05e8 \u05d0\u05d9\u05dc\u05df. \u05d7\u05d5\u05e7\u05e8 \u05d0\u05ea \u05de\u05e2\u05d5\u05e8\u05d1\u05d5\u05ea \u05de\u05e2\u05e8\u05db\u05ea \u05d4\u05d7\u05d9\u05e1\u05d5\u05df \u05d1\u05de\u05d7\u05dc\u05d5\u05ea \u05e0\u05d9\u05d5\u05d5\u05df \u05e2\u05e6\u05d1\u05d9 \u05d5\u05d0\u05ea \u05d4\u05de\u05e0\u05d2\u05e0\u05d5\u05e0\u05d9\u05dd \u05d3\u05e8\u05db\u05dd \u05e4\u05e2\u05d9\u05dc\u05d5\u05ea \u05d2\u05d5\u05e4\u05e0\u05d9\u05ea \u05de\u05e9\u05e4\u05d9\u05e2\u05d4 \u05e2\u05dc \u05e4\u05dc\u05e1\u05d8\u05d9\u05d5\u05ea \u05de\u05d5\u05d7\u05d9\u05ea \u05d5\u05ea\u05d4\u05dc\u05d9\u05db\u05d9 \u05dc\u05de\u05d9\u05d3\u05d4 \u05d5\u05d6\u05d9\u05db\u05e8\u05d5\u05df.","sameAs":["https:\/\/x.com\/EitanOkun"],"url":"https:\/\/www.lbscience.org\/en\/author\/eitan-okun\/"}]}},"_links":{"self":[{"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/posts\/1091","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/users\/134"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/comments?post=1091"}],"version-history":[{"count":7,"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/posts\/1091\/revisions"}],"predecessor-version":[{"id":1172,"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/posts\/1091\/revisions\/1172"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/media\/1167"}],"wp:attachment":[{"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/media?parent=1091"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/categories?post=1091"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lbscience.org\/en\/wp-json\/wp\/v2\/tags?post=1091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}